MedTrace Logo

Targeting Cognition in Early Alzheimer's Disease by Improving Sleep With Trazodone

NCT05282550 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-09-18

No results posted yet for this study

Summary

To investigate the effect of trazodone on sleep, hippocampal-dependent memory and hippocampal excitability. The investigators hypothesize that trazodone will improve total sleep time and proportion of time in Slow Wave Sleep (SWS).

Conditions

  • AMCI - Amnestic Mild Cognitive Impairment
  • Sleep Disturbance

Interventions

DRUG

Trazodone

50mg of trazodone administered for 4 weeks.

DRUG

Placebo

Placebo administered for 4 weeks.

Sponsors & Collaborators

Principal Investigators

  • Barry Greenberg, PhD · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-02
Primary Completion
2027-07-30
Completion
2028-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05282550 on ClinicalTrials.gov